Clinical Trial

Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 10, 2025 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aims to assess the efficacy and safety of the chemotherapy-light combination of glofitamab, polatuzumab vedotin and zanubrutinib (GPZ) in elderly patients with previously untreated diffuse large B-cell lymphoma.
Trial Details
NCT Number NCT07012980
Lead Sponsor Shanghai Zhongshan Hospital
Collaborators: Hoffmann-La Roche, BeiGene
Conditions Diffuse Large B-Cell Lymphoma
Enrollment 38 participants
Start Date 2025-06-01
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-06-10